| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Access to HCV treatments: hurdles not barriers
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
1 |
p. 1
|
artikel
|
| 2 |
ACG 2021
|
Pinion, Sheila
|
|
|
|
1 |
p. 14
|
artikel
|
| 3 |
A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score
|
Jairath, Vipul
|
|
2019
|
|
1 |
p. 63-70
|
artikel
|
| 4 |
Acute oesophageal necrosis
|
Khan, Saad A
|
|
2016
|
|
1 |
p. 84-
1 p.
|
artikel
|
| 5 |
Adapting to a life with Crohn's disease
|
Anderson, Curtiss
|
|
|
|
1 |
p. 14-15
|
artikel
|
| 6 |
Advances in primary sclerosing cholangitis
|
Horsley-Silva, Jennifer L
|
|
2016
|
|
1 |
p. 68-77
10 p.
|
artikel
|
| 7 |
American College of Gastroenterology 2019 annual meeting
|
Pinion, Sheila
|
|
|
|
1 |
p. 12
|
artikel
|
| 8 |
A multidisciplinary personalised paradigm for achalasia
|
Low, Eric E
|
|
|
|
1 |
p. 3-5
|
artikel
|
| 9 |
A non-endoscopic device to sample the oesophageal microbiota: a case-control study
|
Elliott, Daffolyn R Fels
|
|
|
|
1 |
p. 32-42
|
artikel
|
| 10 |
Anti-angiogenic therapy in the setting of TACE: an elusive synergy?
|
Odisio, Bruno C
|
|
2018
|
|
1 |
p. 5-6
|
artikel
|
| 11 |
Artificial intelligence and computer-aided diagnosis in colonoscopy: current evidence and future directions
|
Ahmad, Omer F
|
|
2019
|
|
1 |
p. 71-80
|
artikel
|
| 12 |
Assessing the burden of gastrointestinal disease: room for improvement?
|
Williams, John G
|
|
2016
|
|
1 |
p. 5-6
2 p.
|
artikel
|
| 13 |
A US plan for HCV elimination
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
1 |
p. 1
|
artikel
|
| 14 |
A whole-food exclusion diet as monotherapy for Crohn's disease
|
Sasson, Alexa N
|
|
|
|
1 |
p. 6-7
|
artikel
|
| 15 |
Bowel cancer diagnostic services in the UK: at full capacity?
|
Burki, Talha Khan
|
|
2019
|
|
1 |
p. 15
|
artikel
|
| 16 |
British Society of Gastroenterology Annual Meeting 2016
|
Thorley, Jennifer
|
|
2016
|
|
1 |
p. 10-
1 p.
|
artikel
|
| 17 |
Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial
|
Hamaguchi, Tetsuya
|
|
2018
|
|
1 |
p. 47-56
|
artikel
|
| 18 |
Cartoons for paediatric patients
|
Zajanckauskaite, Estera
|
|
|
|
1 |
p. 12
|
artikel
|
| 19 |
Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial
|
Flanagan, Stuart
|
|
2019
|
|
1 |
p. 32-44
|
artikel
|
| 20 |
Challenges in gastroenterology training in Australia
|
Prince, David S
|
|
|
|
1 |
p. 8-10
|
artikel
|
| 21 |
Changing paradigms in adjuvant treatment of colorectal cancer
|
Lordick, Florian
|
|
2018
|
|
1 |
p. 6-8
|
artikel
|
| 22 |
Cirrhosis and hepatocellular carcinoma at primary hospitals in sub-Saharan Africa: the opportunity of PEN-Plus
|
Gupta, Neil
|
|
|
|
1 |
p. 13-14
|
artikel
|
| 23 |
Closing toilets: more than a public inconvenience
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
1 |
p. 1
|
artikel
|
| 24 |
Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study
|
Breekveldt, Emilie C H
|
|
|
|
1 |
p. 60-68
|
artikel
|
| 25 |
Correction
|
|
|
2016
|
|
1 |
p. e1-
1 p.
|
artikel
|
| 26 |
Correction to Lancet Gastroenterol Hepatol 2017; 2: 877–89
|
|
|
2018
|
|
1 |
p. e1
|
artikel
|
| 27 |
Correction to Lancet Gastroenterol Hepatol 2017; 2: 32–42
|
|
|
|
|
1 |
p. e1
|
artikel
|
| 28 |
Correction to Lancet Gastroenterol Hepatol 2021; 6: 526–27
|
|
|
|
|
1 |
p. e1
|
artikel
|
| 29 |
Correction to Lancet Gastroenterol Hepatol 2023; 8: 1005–14
|
|
|
|
|
1 |
p. e1
|
artikel
|
| 30 |
COVID-19 and liver transplantation: the jury is still out
|
Tavabie, Oliver D
|
|
|
|
1 |
p. 10-11
|
artikel
|
| 31 |
COVID-19 and liver transplantation: the jury is still out – Authors' reply
|
Webb, Gwilym J
|
|
|
|
1 |
p. 11
|
artikel
|
| 32 |
Cytosponge use in risk stratification of Barrett's oesophagus
|
Zakko, Liam
|
|
|
|
1 |
p. 3-4
|
artikel
|
| 33 |
De-escalation of immunomodulator and biological therapy in inflammatory bowel disease
|
Chapman, Thomas P
|
|
|
|
1 |
p. 63-79
|
artikel
|
| 34 |
Direct-acting antivirals for chronic hepatitis C virus genotype 5 and 6 infections
|
Torres, Maria Corina Plaz
|
|
2019
|
|
1 |
p. 5-6
|
artikel
|
| 35 |
DNA testing of pancreatic cyst fluid: is it ready for prime time?
|
Singhi, Aatur D
|
|
|
|
1 |
p. 63-72
|
artikel
|
| 36 |
Effect of an artificial intelligence-assisted system on endoscopic diagnosis of superficial oesophageal squamous cell carcinoma and precancerous lesions: a multicentre, tandem, double-blind, randomised controlled trial
|
Yuan, Xiang-Lei
|
|
|
|
1 |
p. 34-44
|
artikel
|
| 37 |
Effect of diagnosis, surveillance, and treatment of Barrett's oesophagus on health-related quality of life
|
Britton, James
|
|
2018
|
|
1 |
p. 57-65
|
artikel
|
| 38 |
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial
|
Asselah, Tarik
|
|
2019
|
|
1 |
p. 45-51
|
artikel
|
| 39 |
Efficacy of individual and group hypnotherapy in irritable bowel syndrome (IMAGINE): a multicentre randomised controlled trial
|
Flik, Carla E
|
|
2019
|
|
1 |
p. 20-31
|
artikel
|
| 40 |
Efficacy of surgical or endoscopic treatment of idiopathic achalasia: a systematic review and network meta-analysis
|
Mundre, Pradeep
|
|
|
|
1 |
p. 30-38
|
artikel
|
| 41 |
Endoscopic screening for oesophageal cancer: empowering artificial intelligence with a high-quality examination
|
Leggett, Cadman L
|
|
|
|
1 |
p. 4-5
|
artikel
|
| 42 |
End-stage liver disease in eastern Europe and central Asia: action is needed
|
Vento, Sandro
|
|
2016
|
|
1 |
p. 8-9
2 p.
|
artikel
|
| 43 |
Enhanced recovery for liver transplantation: recommendations from the 2022 International Liver Transplantation Society consensus conference
|
Pollok, Joerg M
|
|
|
|
1 |
p. 81-94
|
artikel
|
| 44 |
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial
|
Sandborn, William J
|
|
|
|
1 |
p. 43-55
|
artikel
|
| 45 |
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study
|
Vermeire, Severine
|
|
|
|
1 |
p. 28-37
|
artikel
|
| 46 |
Etrolizumab for ulcerative colitis: beyond what meets the eye
|
Agrawal, Manasi
|
|
|
|
1 |
p. 2-4
|
artikel
|
| 47 |
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials
|
Rubin, David T
|
|
|
|
1 |
p. 17-27
|
artikel
|
| 48 |
Evidence of reducing ethanol content in beverages to reduce harmful use of alcohol
|
Rehm, Jürgen
|
|
2016
|
|
1 |
p. 78-83
6 p.
|
artikel
|
| 49 |
Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial
|
Johnsen, Peter Holger
|
|
2018
|
|
1 |
p. 17-24
|
artikel
|
| 50 |
Fermented foods: fad or favourable addition to the diet?
|
Staudacher, Heidi M
|
|
2019
|
|
1 |
p. 19
|
artikel
|
| 51 |
Flux Gourmet: a visual feast with a starved social mission
|
Moody, Joe
|
|
|
|
1 |
p. 18
|
artikel
|
| 52 |
From stigma to solutions: fighting for effective alcohol policy
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
1 |
p. 1
|
artikel
|
| 53 |
Functional gastrointestinal disorders: what's new for Rome IV?
|
Drossman, Douglas A
|
|
2016
|
|
1 |
p. 6-8
3 p.
|
artikel
|
| 54 |
Genetic predisposition to gastrointestinal polyposis: syndromes, tumour features, genetic testing, and clinical management
|
Valle, Laura
|
|
|
|
1 |
p. 68-82
|
artikel
|
| 55 |
Genotype 4 and the global challenge of hepatitis C treatment
|
Ryder, Stephen
|
|
2016
|
|
1 |
p. 3-4
2 p.
|
artikel
|
| 56 |
Global burden of inflammatory bowel disease
|
Jairath, Vipul
|
|
|
|
1 |
p. 2-3
|
artikel
|
| 57 |
Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies
|
Xiao, Amy Y
|
|
2016
|
|
1 |
p. 45-55
11 p.
|
artikel
|
| 58 |
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis
|
Quek, Jingxuan
|
|
|
|
1 |
p. 20-30
|
artikel
|
| 59 |
Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial
|
Newsome, Philip Noel
|
|
2018
|
|
1 |
p. 25-36
|
artikel
|
| 60 |
Gut feelings
|
Thorley, Jennifer
|
|
2016
|
|
1 |
p. 14-
1 p.
|
artikel
|
| 61 |
Gutted
|
Bell, Andrew
|
|
2016
|
|
1 |
p. 13-
1 p.
|
artikel
|
| 62 |
Haemopoietic stem cell therapy in cirrhosis: the end of the story?
|
Lanthier, Nicolas
|
|
2018
|
|
1 |
p. 3-5
|
artikel
|
| 63 |
Harm reduction and viral hepatitis in the Philippines
|
Burki, Talha Khan
|
|
|
|
1 |
p. 16
|
artikel
|
| 64 |
Harnessing the power of hepatitis B screening programmes: the I REACH OUT model
|
Lok, James
|
|
|
|
1 |
p. 15-17
|
artikel
|
| 65 |
Has the COVID-19 pandemic changed endoscopy in the UK forever?
|
Rees, Colin
|
|
|
|
1 |
p. 6-8
|
artikel
|
| 66 |
Hepatitis C among men who have sex with men: knowing your epidemic
|
Rauch, Andri
|
|
|
|
1 |
p. 5-6
|
artikel
|
| 67 |
Hepatitis case finding among migrants in primary care
|
Hickman, Matthew
|
|
2019
|
|
1 |
p. 3-4
|
artikel
|
| 68 |
Hepatitis C incidence 3 years after implementation of an educate, test, and treat programme in an Egyptian village
|
Shiha, Gamal
|
|
2019
|
|
1 |
p. 13-14
|
artikel
|
| 69 |
How can I improve my gut health via non-dietary means?
|
Loughman, Amy
|
|
|
|
1 |
p. 20
|
artikel
|
| 70 |
How to live when you could be dead
|
Bisbas, Georgia
|
|
|
|
1 |
p. 19
|
artikel
|
| 71 |
Immune checkpoint inhibitors in colorectal cancer: dream and reality
|
André, Thierry
|
|
|
|
1 |
p. 4-6
|
artikel
|
| 72 |
Implementation of a liver health check in people with type 2 diabetes
|
Abeysekera, Kushala W M
|
|
|
|
1 |
p. 83-91
|
artikel
|
| 73 |
Improving liver cancer care across Europe
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
1 |
p. 1
|
artikel
|
| 74 |
Incidence and enteral feed antecedents of severe neonatal necrotising enterocolitis across neonatal networks in England, 2012–13: a whole-population surveillance study
|
Battersby, Cheryl
|
|
|
|
1 |
p. 43-51
|
artikel
|
| 75 |
Inflammatory bowel disease in Lebanon: a plea for help
|
Mourad, Fadi H
|
|
|
|
1 |
p. 13
|
artikel
|
| 76 |
Infliximab or ciclosporin for acute severe ulcerative colitis?
|
Ananthakrishnan, Ashwin N
|
|
2016
|
|
1 |
p. 2-3
2 p.
|
artikel
|
| 77 |
Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial
|
Williams, John G
|
|
2016
|
|
1 |
p. 15-24
10 p.
|
artikel
|
| 78 |
Integrating artificial intelligence into endoscopy training: opportunities, challenges, and strategies
|
Grover, Samir C
|
|
|
|
1 |
p. 11-13
|
artikel
|
| 79 |
Interim evaluation of the colorectal cancer screening programme in the Netherlands
|
Hoffmeister, Michael
|
|
|
|
1 |
p. 8-9
|
artikel
|
| 80 |
Internal conflict
|
Bianchi, Andrew
|
|
2016
|
|
1 |
p. 14-
1 p.
|
artikel
|
| 81 |
Ironing out unmet need in genetic haemochromatosis
|
The Lancet Gastroenterology & Hepatology,
|
|
2019
|
|
1 |
p. 1
|
artikel
|
| 82 |
Is hypnotherapy helpful for irritable bowel syndrome in primary and secondary care?
|
Palsson, Olafur S
|
|
2019
|
|
1 |
p. 2-3
|
artikel
|
| 83 |
Key performance indicators are needed for polypectomy
|
Klein, Amir
|
|
|
|
1 |
p. 6-8
|
artikel
|
| 84 |
Launch of the Coalition for Global Hepatitis Elimination: a recommendation of the Lancet Gastroenterology & Hepatology Commission
|
Ward, John W
|
|
|
|
1 |
p. 8-10
|
artikel
|
| 85 |
Liver transplantation in the USA: ethical issues
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
1 |
p. 1
|
artikel
|
| 86 |
Living in a microbe's world
|
Blott, Jonathan
|
|
|
|
1 |
p. 11
|
artikel
|
| 87 |
Making optical biopsy a clinical reality in colonoscopy
|
East, James E
|
|
2018
|
|
1 |
p. 10-12
|
artikel
|
| 88 |
Management of hepatitis C virus infection in the Asia-Pacific region: an update
|
Lim, Seng Gee
|
|
|
|
1 |
p. 52-62
|
artikel
|
| 89 |
Management of malignant bowel obstruction
|
Mercadante, Sebastiano
|
|
|
|
1 |
p. 14
|
artikel
|
| 90 |
Management of malignant bowel obstruction
|
Gupta, Arjun
|
|
|
|
1 |
p. 14-15
|
artikel
|
| 91 |
Management of malignant bowel obstruction – Authors' reply
|
Krouse, Robert S
|
|
|
|
1 |
p. 15
|
artikel
|
| 92 |
Microbiome analysis: ready for clinical use?
|
The Lancet Gastroenterology & Hepatology,
|
|
2018
|
|
1 |
p. 1
|
artikel
|
| 93 |
Minimum alcohol pricing in Scotland
|
The Lancet Gastroenterology & Hepatology,
|
|
2018
|
|
1 |
p. 1
|
artikel
|
| 94 |
Modifiable pathways for colorectal cancer: a mendelian randomisation analysis
|
Cornish, Alex J
|
|
|
|
1 |
p. 55-62
|
artikel
|
| 95 |
NAFLD prevalence and severity in overweight and obese populations
|
Francque, Sven M A
|
|
|
|
1 |
p. 2-3
|
artikel
|
| 96 |
Necrotising enterocolitis: better data, still many questions
|
Hall, Nigel J
|
|
|
|
1 |
p. 6-7
|
artikel
|
| 97 |
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial
|
Hu, Huabin
|
|
|
|
1 |
p. 38-48
|
artikel
|
| 98 |
New restrictions on JAK inhibitors in the EU
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
1 |
p. 1
|
artikel
|
| 99 |
Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa
|
Shiha, Gamal
|
|
|
|
1 |
p. 57-64
|
artikel
|
| 100 |
Non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis
|
Zhou, Yu-Jie
|
|
|
|
1 |
p. 9-10
|
artikel
|
| 101 |
Non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis
|
Choy, Kay Weng
|
|
|
|
1 |
p. 9
|
artikel
|
| 102 |
Of milk and microbes
|
Burki, Talha Khan
|
|
2018
|
|
1 |
p. 16
|
artikel
|
| 103 |
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial
|
Waked, Imam
|
|
2016
|
|
1 |
p. 36-44
9 p.
|
artikel
|
| 104 |
Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial
|
Asselah, Tarik
|
|
2016
|
|
1 |
p. 25-35
11 p.
|
artikel
|
| 105 |
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
|
Kudo, Masatoshi
|
|
2018
|
|
1 |
p. 37-46
|
artikel
|
| 106 |
Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study
|
Atia, Ohad
|
|
|
|
1 |
p. 31-42
|
artikel
|
| 107 |
Paediatric multiple magnet ingestion
|
van Waas, Marjolein
|
|
|
|
1 |
p. 80
|
artikel
|
| 108 |
Pathogenesis and novel treatment options for non-alcoholic steatohepatitis
|
Wong, Vincent Wai-Sun
|
|
2016
|
|
1 |
p. 56-67
12 p.
|
artikel
|
| 109 |
Personalised medicine in Crohn's disease
|
Noor, Nurulamin M
|
|
|
|
1 |
p. 80-92
|
artikel
|
| 110 |
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial
|
Garin, Etienne
|
|
|
|
1 |
p. 17-29
|
artikel
|
| 111 |
Pharmacy-led hepatitis C treatment pathways to help ensure elimination
|
Gunn, Jack
|
|
2019
|
|
1 |
p. 12-13
|
artikel
|
| 112 |
Place of death and factors associated with hospital death in patients who have died from liver disease in England: a national population-based study
|
Peng, Jen-Kuei
|
|
2019
|
|
1 |
p. 52-62
|
artikel
|
| 113 |
Practicalities accessing precision medicine in biliary tract cancer
|
Edeline, Julien
|
|
|
|
1 |
p. 5-6
|
artikel
|
| 114 |
Preoperative drainage for perihilar cholangiocarcinoma
|
Odisio, Bruno C
|
|
2019
|
|
1 |
p. 10-11
|
artikel
|
| 115 |
Preoperative drainage for perihilar cholangiocarcinoma
|
Singh, Akash
|
|
2019
|
|
1 |
p. 10
|
artikel
|
| 116 |
Preoperative drainage for perihilar cholangiocarcinoma – Authors' reply
|
Coelen, Robert J S
|
|
2019
|
|
1 |
p. 11-12
|
artikel
|
| 117 |
Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis
|
Jin, Fengyi
|
|
|
|
1 |
p. 39-56
|
artikel
|
| 118 |
Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis
|
Hong, Tzu-Chan
|
|
|
|
1 |
p. 56-67
|
artikel
|
| 119 |
Radioembolisation with personalised dosimetry: improving outcomes for patients with advanced hepatocellular carcinoma
|
Lewandowski, Robert J
|
|
|
|
1 |
p. 2-3
|
artikel
|
| 120 |
Redefining fatty liver disease: an international patient perspective
|
Shiha, Gamal
|
|
|
|
1 |
p. 73-79
|
artikel
|
| 121 |
Research in Brief
|
Baker, Holly
|
|
|
|
1 |
p. 16
|
artikel
|
| 122 |
Research in brief
|
Baker, Holly
|
|
2018
|
|
1 |
p. 15
|
artikel
|
| 123 |
Research in brief
|
Baker, Holly
|
|
2016
|
|
1 |
p. 11-
1 p.
|
artikel
|
| 124 |
Research in brief
|
Baker, Holly
|
|
2019
|
|
1 |
p. 18
|
artikel
|
| 125 |
Research in brief
|
Baker, Holly
|
|
|
|
1 |
p. 9
|
artikel
|
| 126 |
Research in brief
|
Baker, Holly
|
|
|
|
1 |
p. 13
|
artikel
|
| 127 |
Research in brief
|
Baker, Holly
|
|
|
|
1 |
p. 16
|
artikel
|
| 128 |
Research in Brief
|
Baker, Holly
|
|
|
|
1 |
p. 19
|
artikel
|
| 129 |
Resuming liver transplantation amid the COVID-19 pandemic
|
Thorburn, Douglas
|
|
|
|
1 |
p. 12-13
|
artikel
|
| 130 |
Retooling treatment in oligometastatic oesophageal cancer
|
Cammarota, Antonella
|
|
|
|
1 |
p. 5-7
|
artikel
|
| 131 |
Rising resistance: antibiotic choices for Helicobacter pylori infection
|
Fauzia, Kartika Afrida
|
|
|
|
1 |
p. 7-8
|
artikel
|
| 132 |
Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study
|
Ross-Innes, Caryn S
|
|
|
|
1 |
p. 23-31
|
artikel
|
| 133 |
Robotic versus laparoscopic surgery for middle and low rectal cancer
|
Meyer, Jeremy
|
|
|
|
1 |
p. 11
|
artikel
|
| 134 |
Robotic versus laparoscopic surgery for middle and low rectal cancer
|
Kammar, Praveen S
|
|
|
|
1 |
p. 11-12
|
artikel
|
| 135 |
Robotic versus laparoscopic surgery for middle and low rectal cancer – Authors' reply
|
Xu, Jianmin
|
|
|
|
1 |
p. 12-13
|
artikel
|
| 136 |
Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial
|
Pose, Elisa
|
|
|
|
1 |
p. 31-41
|
artikel
|
| 137 |
Skin changes in long-term Wilson's disease
|
Yin, James Liu
|
|
|
|
1 |
p. 92
|
artikel
|
| 138 |
Stool as a treatment for IBS: more questions than answers?
|
Ford, Alexander C
|
|
2018
|
|
1 |
p. 2-3
|
artikel
|
| 139 |
Surgery versus conservative management for recurrent and ongoing left-sided diverticulitis (DIRECT trial): an open-label, multicentre, randomised controlled trial
|
van de Wall, Bryan J M
|
|
|
|
1 |
p. 13-22
|
artikel
|
| 140 |
Sustainability in gastrointestinal endoscopy
|
Baddeley, Robin
|
|
|
|
1 |
p. 9-12
|
artikel
|
| 141 |
Séverine Vermeire: advancing patient-centred research in IBD
|
Thorley, Jennifer
|
|
|
|
1 |
p. 17
|
artikel
|
| 142 |
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial
|
Liu, Qi
|
|
|
|
1 |
p. 45-55
|
artikel
|
| 143 |
Tackling the burden of preventable liver disease in the USA
|
Bhala, Neeraj
|
|
|
|
1 |
p. 9-10
|
artikel
|
| 144 |
Talking faecal transplant
|
Mohammadi, Dara
|
|
2016
|
|
1 |
p. 12-
1 p.
|
artikel
|
| 145 |
The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial
|
Yanai, Henit
|
|
|
|
1 |
p. 49-59
|
artikel
|
| 146 |
The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
|
|
|
|
|
1 |
p. 17-30
|
artikel
|
| 147 |
The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017
|
|
|
|
|
1 |
p. 42-54
|
artikel
|
| 148 |
The intestinal barrier in disorders of the central nervous system
|
Pellegrini, Carolina
|
|
|
|
1 |
p. 66-80
|
artikel
|
| 149 |
The Lancet Gastroenterology & Hepatology: putting the inside out
|
The Lancet Gastroenterology & Hepatology,
|
|
2016
|
|
1 |
p. 1-
1 p.
|
artikel
|
| 150 |
The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease
|
Mendez-Sanchez, Nahum
|
|
|
|
1 |
p. 65-72
|
artikel
|
| 151 |
The Liver Meeting 2022
|
Thomas, Hugh
|
|
|
|
1 |
p. 15
|
artikel
|
| 152 |
The Liver Meeting 2016
|
Brierley, Rob
|
|
|
|
1 |
p. 8
|
artikel
|
| 153 |
The Liver Meeting 2023
|
Brierley, Rob
|
|
|
|
1 |
p. 18
|
artikel
|
| 154 |
The Liver Meeting Digital Experience 2021
|
Thomas, Hugh
|
|
|
|
1 |
p. 15
|
artikel
|
| 155 |
The Liver Meeting Digital Experience
|
Thomas, Hugh
|
|
|
|
1 |
p. 15
|
artikel
|
| 156 |
The microbiome as a potential biomarker for oesophageal adenocarcinoma
|
Abrams, Julian A
|
|
|
|
1 |
p. 4-6
|
artikel
|
| 157 |
The painful reality of end-stage liver disease in NASH
|
Ratziu, Vlad
|
|
2018
|
|
1 |
p. 8-10
|
artikel
|
| 158 |
The phases of hepatitis C elimination: achieving WHO elimination targets
|
Pedrana, Alisa
|
|
|
|
1 |
p. 6-8
|
artikel
|
| 159 |
The twists and turns of colorectal cancer screening
|
Mohammadi, Dara
|
|
|
|
1 |
p. 10-11
|
artikel
|
| 160 |
The ultimate therapy
|
De Ambrogi, Marco
|
|
|
|
1 |
p. 15-16
|
artikel
|
| 161 |
The Year My Life Went Down the Toilet
|
Trethewey, Fio
|
|
|
|
1 |
p. 21
|
artikel
|
| 162 |
25th UEG Week
|
Brierley, Rob
|
|
2018
|
|
1 |
p. 14
|
artikel
|
| 163 |
Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease
|
Rowe, Ian A
|
|
2018
|
|
1 |
p. 66-72
|
artikel
|
| 164 |
Towards more efficient assessment of ulcerative colitis drugs
|
Carbonnel, Franck
|
|
2019
|
|
1 |
p. 8-9
|
artikel
|
| 165 |
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)
|
Lee, Choong-kun
|
|
|
|
1 |
p. 56-65
|
artikel
|
| 166 |
Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium
|
Shen, Bo
|
|
|
|
1 |
p. 69-95
|
artikel
|
| 167 |
UEG Week 2018
|
Brierley, Rob
|
|
2019
|
|
1 |
p. 16-17
|
artikel
|
| 168 |
UEG Week 2019
|
Feetham, Laura
|
|
|
|
1 |
p. 11
|
artikel
|
| 169 |
Unmet needs in end-of-life care for chronic liver disease
|
Thomas, Tom
|
|
2019
|
|
1 |
p. 6-7
|
artikel
|
| 170 |
Update on the mesentery: structure, function, and role in disease
|
Coffey, J Calvin
|
|
|
|
1 |
p. 96-106
|
artikel
|
| 171 |
Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial
|
Bang, Ji Young
|
|
|
|
1 |
p. 22-33
|
artikel
|
| 172 |
Upfront necrosectomy for infected necrotising pancreatitis: a promising strategy?
|
Gunjan, Deepak
|
|
|
|
1 |
p. 2-3
|
artikel
|
| 173 |
USPSTF recommends expansion of colorectal cancer screening
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
1 |
p. 1
|
artikel
|
| 174 |
Vedolizumab in paediatric IBD: a huge step forward but not there yet
|
Klomberg, Renz C W
|
|
|
|
1 |
p. 3-5
|
artikel
|
| 175 |
Virtual ACG 2020
|
Pinion, Sheila
|
|
|
|
1 |
p. 14
|
artikel
|
| 176 |
What drives the hypoalgesic effect of neurostimulation?
|
Albusoda, Ahmed
|
|
2018
|
|
1 |
p. 13
|
artikel
|
| 177 |
When is elective resection after acute diverticulitis reasonable?
|
Schultz, Johannes Kurt
|
|
|
|
1 |
p. 2-3
|
artikel
|
| 178 |
When less is more: dosing simvastatin in decompensated cirrhosis
|
Simon, Tracey G
|
|
|
|
1 |
p. 3-5
|
artikel
|
| 179 |
27 years of stomach cancer: painting a global picture
|
Petrillo, Angelica
|
|
|
|
1 |
p. 5-6
|
artikel
|
Tijdschrift beschrijving